Millennium Management LLC Trims Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Millennium Management LLC lowered its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 47.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 586,810 shares of the company's stock after selling 533,153 shares during the quarter. Millennium Management LLC owned about 0.69% of Syndax Pharmaceuticals worth $7,758,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Virtus ETF Advisers LLC lifted its holdings in shares of Syndax Pharmaceuticals by 18.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,278 shares of the company's stock worth $70,000 after purchasing an additional 827 shares during the period. E Fund Management Co. Ltd. increased its holdings in Syndax Pharmaceuticals by 14.4% in the 4th quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company's stock worth $167,000 after buying an additional 1,583 shares during the period. China Universal Asset Management Co. Ltd. raised its position in Syndax Pharmaceuticals by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company's stock worth $239,000 after buying an additional 1,732 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Syndax Pharmaceuticals by 3.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,748 shares of the company's stock worth $706,000 after buying an additional 1,811 shares during the last quarter. Finally, R Squared Ltd acquired a new stake in Syndax Pharmaceuticals during the 4th quarter valued at approximately $26,000.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on SNDX. Wall Street Zen upgraded shares of Syndax Pharmaceuticals to a "sell" rating in a research note on Tuesday, May 6th. JPMorgan Chase & Co. increased their price target on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an "overweight" rating in a research report on Thursday, March 20th. HC Wainwright reiterated a "buy" rating and set a $51.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, March 4th. Scotiabank upped their target price on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a research note on Tuesday, May 6th. Finally, Citigroup dropped their target price on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $35.91.

Syndax Pharmaceuticals Price Performance

SNDX stock traded up $0.04 during mid-day trading on Friday, reaching $10.66. 873,721 shares of the company's stock were exchanged, compared to its average volume of 2,276,037. The company has a market cap of $917.26 million, a price-to-earnings ratio of -2.94 and a beta of 0.82. Syndax Pharmaceuticals, Inc. has a 12-month low of $8.58 and a 12-month high of $25.07. The stock's 50 day moving average is $11.54 and its 200 day moving average is $13.48.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($1.04) by $0.06. The company had revenue of $20.04 million for the quarter, compared to analysts' expectations of $15.88 million. The firm's revenue for the quarter was up 1900.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.85) EPS. On average, research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).